In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 4, 2000, Pages 317-319

  Yildiran, S T ^a,c   Saracli, M A ^c   Fothergill, A W ^a   Rinaldi, M G ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CRYPTOCOCCUS NEOFORMANS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; TURKEY (REPUBLIC);

EID: 0034015295     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050484     Document Type: Article

References (18)

1. 1. Zeind CS, Cleveland KO, Menon M, Brown JR, Solomon DK: Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Pharmacotherapy (1996) 16:547-561
2. 2. Kwong-Chung KJ, Kozel TR, Edman JC, Polacheck I, Ellis D, Shinoda T, Dromer F: Recent advances in biology and immunology of Cryptococcus neoformans. Journal of Medical and Veterinary Mycology (1992) 30, Supplement 1:133-142
3. 3. Franzot SP, Fries BC, Cleare W, Casadevall A: Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D. Journal of Clinical Microbiology (1998) 36:2200-2204
4. 4. Franzot SP, Salkin IF, Casadevall A: Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. Journal of Clinical Microbiology (1999) 37:838-840
5. 5. Kwong-Chung KJ, Bennett JE: Medical mycology. Lea & Febiger, Malvern, PA (1992) p 399
6. 6. Lazera MS, Pires FDA, Camillo-Coura L, Nishikawa MM, Bezerra CCF, Trilles L, Wanke B: Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees. Journal of Medical and Veterinary Mycology (1996) 34:127-131
7. 7. Pinner RW, Hajjeh RA, Powderly WG: Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clinical Infectious Diseases (1995) 21, Supplement 1:103-107
8. 8. Garcia-Hermoso D, Mathoulin-Pélissier S, Couprie B, Ronin O, Dupont B, Dromer F: DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D. Journal of Clinical Microbiology (1997) 35:2683-2685
9. 9. Yamamoto Y, Kohno S, Koga H, Kakeya H, Tomono K, Kaku M, Yamazaki T, Arisawa M, Hara K: Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. Journal of Clinical Microbiology (1995) 33:3328-3332
10. 10. Franzot SP, Hamdan JS: In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrobial Agents and Chemotherapy (1996) 40:822-824
11. 11. Fromtling RA, Abruzzo GK, Ruiz A: Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico. Mycopathologia (1989) 106:163-166
12. 12. Yildiran ST, Saracli MA, Gonlum A, Gun H: Isolation of Cryptococcus neoformans var. neoformans from pigeon droppings collected throughout Turkey. Medical Mycology (1998) 36:391-394
13. 13. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Villanova, PA (1997)
14. 14. Kwong-Chung KJ, Polacheck I, Bennett JE: Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). Journal of Clinical Microbiology (1992) 15:535-537
15. 15. Galgiani JN, Lewis ML: In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrobial Agents and Chemotherapy (1997) 41:180-183
16. 16. Espinel-Ingroff A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Journal of Clinical Microbiology (1998) 36:2950-2956
17. 17. Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, Tumberland M, Mbidde EK, Ghannoum MA: In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrobial Agents and Chemotherapy (1999) 43:169-171
18. 18. Nguyen MH, Yu CY: In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrobial Agents and Chemotherapy (1998) 42:471-472